BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi

BioAge Labs price target lowered at Jefferies after Novo trial miss

BioAge Labs price target lowered to $50 from $60 at Oppenheimer

BioAge Labs Down over 61%, on Pace for Largest Percent Decrease Since December 2024

Sales of Leqembi® Totaled 29.3 Billion Yen in the Second Quarter 2026

Bioage Labs Principal Accounting Officer Shane Barton Disposes of 62,566 Common Shares for $1,578,254.20

BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus

Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)

BioAge doses first participant in Phase 2 QUELL-CV trial of NLRP3 inhibitor BGE-102

Bioage Labs - Topline Data From Quell-Cv Trial Anticipated in Second Half of 2026

Bioage Labs Announces First Participant Dosed in Quell-Cv, a Phase 2 Proof-of-Concept Trial of Bge-102, a Novel Oral Nlrp3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Bioage Labs - to Initiate Phase 1B/2a Trial of Bge-102 in Dme in Mid-2026

BioAge Labs Shareholders Reelect Directors, Ratify Auditor

BioAge Labs shareholders re-elect three directors at annual meeting

BioAge Labs posts preclinical data on oral NLRP3 inhibitor BGE-102 in diabetic retinopathy model

BioAge Labs posts Phase 1 BGE-102 presentation showing anti-inflammatory activity in obesity cohort

Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target

BioAge Labs Initiated at Buy by Roth Capital